DOLBY LABORATORIES, INC.
In the published model solve dated 2026-Q2, anchored at $61.50, DOLBY LABORATORIES, INC. (DLB) is priced for +15.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Licensing is 93.0% of revenue, and the annual report states the clock under it without decoration: ⟦"Patents eventually expire"⟧, so the business has to keep replacing coverage it is losing. • Revenue for the first half of fiscal 2026 rose about 2%, while operating profit went backwards to 175.1 million dollars from 187.6 million, because the expense base is growing faster than the royalty base. • Fiscal third-quarter results are due on July 30, 2026, and they arrive against $594.7M in net cas
Is DLB overvalued? See what's priced in →
404 institutional managers reported holding DLB in 13F filings for the quarter ended 2026-03-31. Together they hold about 61% of the company; the top 10 hold 37%. 62 opened new positions that quarter. Held by Vanguard Group, BlackRock, Morgan Stanley, among others. On the short side, 5.8M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
DLB has cut its share count 6.1% over the past five years, spending $1.20B on repurchases. It pays a dividend, and has for 12 years running, raised 8 years straight; the current rate is $1.32 a share annually. Cash returned over the past three years: $335.68M in dividends and $445.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at DLB over the trailing three years: 2024: 1 buy totaling $0k. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
DLB's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -9.8% | +1.7% |
| 2023-11-18 | -8.0% | +3.4% |
| 2024-02-03 | -3.5% | +2.8% |
| 2024-05-03 | +5.8% | -2.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
DLB's latest 8-K filings: 2026-08-27 (items 5.02, 7.01, 8.01, 9.01); 2026-07-30 (items 2.02, 8.01, 9.01); 2026-04-30 (items 2.02, 8.01, 9.01); 2026-02-06 (items 5.07); 2026-01-29 (items 2.02, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.